Novel Approaches to Thyroid Cancer Treatment and Response Assessment

The incidence of thyroid cancer has been increasing. After total thyroidectomy of well-differentiated thyroid tumors with intermediate- or high-risk features on pathology, radioiodine remains one of the mainstays of therapy for both thyroid remnant ablation as well as for treatment of metastatic dis...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in nuclear medicine 2016-03, Vol.46 (2), p.109-118
Main Authors: Grewal, Ravinder K., MD, Ho, Alan, MD, PhD, Schöder, Heiko, MD
Format: Article
Language:English
Subjects:
Animals
Diagnostic Imaging
Humans
Molecular Targeted Therapy
Radiology
Thyroid Neoplasms - diagnosis
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - pathology
Thyroid Neoplasms - therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The incidence of thyroid cancer has been increasing. After total thyroidectomy of well-differentiated thyroid tumors with intermediate- or high-risk features on pathology, radioiodine remains one of the mainstays of therapy for both thyroid remnant ablation as well as for treatment of metastatic disease. SPECT/CT, a relatively new modality, has been shown to play a pivotal role predominantly in the post-therapy setting by changing the risk stratification of patients with thyroid cancer. In the case of radioiodine treatment failure, FDG-PET/CT may provide prognostic information based on extent and intensity of metabolically active metastatic sites as well as serve as an important imaging test for response assessment in patients treated with chemotherapy, targeted therapies, or radiotherapy, thereby affecting patient management in multiple ways. The role of newer redifferentiation drugs has been evaluated with the use of I-124 PET/CT.
ISSN:0001-2998
1558-4623
DOI:10.1053/j.semnuclmed.2015.10.010